Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study

BACKGROUND

Velusetrag is an orally active 5-HT(4) receptor agonist of potential benefit in treating chronic idiopathic constipation.

AIM

To evaluate the efficacy, safety and tolerability of velusetrag in chronic idiopathic constipation.

METHODS

After a 2-week baseline period, patients [<3 spontaneous bowel movements (SBM)/week] received placebo or velusetrag (15, 30 or 50 mg) daily for 4 weeks in a randomized, double-blind design, followed by a 1-week follow-up period. The primary endpoint was the change from baseline in weekly SBM frequency averaged over the 4-week treatment period.

RESULTS

Patients receiving velusetrag (15, 30 and 50 mg) achieved statistically and clinically significant increases in weekly SBM frequency relative to those receiving placebo. Mean increases were 3.6, 3.3 and 3.5 SBM/week respectively, compared with 1.4 SBM/week for placebo (P < 0.0001). Statistically significant increases in the weekly frequency of complete SBM (CSBM) were also reported (mean increases of 2.3, 1.8 and 2.3 for 15, 30 and 50 mg velusetrag respectively, compared with 0.6 for placebo). Common adverse events associated with velusetrag were diarrhoea, headache, nausea and vomiting, generally occurring during the initial days of dosing.

CONCLUSION

Velusetrag was efficacious and well tolerated in patients with chronic idiopathic constipation (ClinicalTrials.gov identifier NCT00391820).

Occupational exposure to solvents and cognitive performance in the GAZEL cohort: preliminary results

BACKGROUND

The impact of occupational exposure to solvents on cognitive ageing remains unclear. We examined whether long-term occupational exposure is associated with poor cognitive performance in late midlife.

METHODS

Participants in the GAZEL cohort, set up in 1989, are employees of the French national electricity and gas company. Data on the working environment were used to create measures of cumulative exposures to solvents using a job-exposure matrix. In 2002-2004, cognitive performance was assessed using the Digit Symbol Substitution Test (DSST) and the Mini Mental State Examination in 5,242 participants (aged 55-65 years).

RESULTS

In cross-sectional analysis using multiple logistic regression, there was a greater risk of poor cognitive performance (DSST score <25th percentile) among those with high exposure to benzene (OR = 1.58; 95% CI 1.31-1.90) and the grouped categories of chlorinated (OR = 1.39; 95% CI 1.3-2.3), aromatic (OR = 1.76; 95% CI 1.08-2.87), and petroleum solvents (OR = 1.50; 95% CI 1.23-1.81).

CONCLUSIONS

These results suggest that occupational exposures to solvents may be associated later in life with cognitive impairment, even after taking into account the effects of education, employment grade, and numerous health factors.

The French Musculoskeletal Disorders Surveillance Program: Pays de la Loire network

Objectives:

An epidemiological surveillance system for work-related musculoskeletal disorders (MSDs) was implemented in 2002 in France’s Pays de la Loire region to assess the incidence and prevalence of MSDs in the general and working populations, identify levels of exposure to occupational risk factors and investigate the proportion of cases attributable to work exposure.

Methods:

The program combines (1) surveillance of sentinel health events in the general population (carpal tunnel syndrome (CTS) was the sentinel event for upper limb MSDs), (2) assessment of the prevalence of the main upper limb MSDs and their risk factors in the workplace based on a network of occupational physicians and (3) registration of the notification of work-related diseases (WRDs).

Results:

1168 incident cases of CTS were included over a 3 year period. The estimated incidence of CTS was 1.00 per 1000 person-years in those aged 20–59 years (0.60 in men and 1.40 in women). The incidence rate was higher in employed than unemployed persons in the year of diagnosis (0.6 per 1000 vs 0.3 in men and 1.7 vs 0.8 in women). The occupational physician network noted high prevalence rates: 11% of men and 15% of women had at least one of the six main upper limb clinically-diagnosed MSDs. The WRD survey showed that MSDs represented 65% of notified WRDs.

Conclusion:

The Pays de la Loire program plays a significant role in informing the authorities and the public about the state of current MSDs. It is planned to extend it to a routine national surveillance program.